Search

Search Results
Results 4741 - 4750 of 4752 for multiple sclerosis
  • White Paper - 28 Jan 2020
    This article discusses gamma Synuclein aggregation in neurodegenerative diseases.
  • White Paper - 6 Jun 2019
    Metabotropic glutamate receptors are exciting therapeutic targets due to their involvement in cardiovascular and neurological diseases, and their widespread expression.
  • Health - 27 Feb 2019
    Rickets has been around for centuries, but its roots as a symptom of vitamin D deficiency began only in the 17th century, when Francis Glisson published his findings on the disease and proposed that...
  • News - 25 Jul 2012
    Elan Corporation, plc today reported its second quarter and first half 2012 financial results.
  • Drug - 24 Oct 2025
    Consumer Medicine Information (CMI) about Trajentamet intended for persons living in Australia.
  • Drug - 6 Aug 2025
    Consumer Medicine Information (CMI) about Abrilada intended for persons living in Australia.
  • White Paper - 24 Jul 2025
    Explore how cytokines contribute to autoimmune disease development and discover emerging therapies.
  • White Paper - 28 Oct 2019
    Reviewing the ligands mostly used as experimental tools for cannabinoid receptors can give a wider understanding of endocannabinoid systems.
  • Supplier - 8 Dec 2025
    LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives.
  • Supplier - 14 Dec 2017
    Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.